Browse by Medical Category
Research at Mass General
The Wang Laboratory in the Center for Transplantation Sciences (CTS) at Massachusetts General Hospital is dedicated to developing diphtheria toxin-based recombinant immunotoxins/fusion toxins for cancer immunotherapy, and mechanisms for studying transplantation tolerance and autoimmune diseases.
Zhirui Wang, DVM, PhDHead, Wang Laboratory, Center for Transplantation Sciences (CTS)Assistant Immunologist, Massachusetts General Hospital Assistant Professor of Surgery, Harvard Medical School
Zhirui Wang, DVM, PhD, completed his doctorate in molecular biology from Justus-Liebig-University of Giessen in Germany in 1995. Dr. Wang completed his Doctor of Veterinary Medicine training in 1982 and his Master of Science in Veterinary Preventive Medicine in 1988 from Shanxi Agricultural University in China. He gained expertise in protein engineering and targeted drug delivery systems through his post-doctoral training in the laboratory of David Neville, MD, at the National Institutes of Health, before joining the Mass General Transplantation Biology Research Center (now known as the Center for Transplantation Sciences) in 2007. Currently, Dr. Wang holds appointments as assistant professor of surgery at Harvard Medical School and assistant immunologist at Mass General.
Zhaohui Wang, DVMHuiping ZhangQi Huang
The Wang Laboratory leads the following research projects:
Diphtheria toxin-based anti-human CCR4 immunotoxin for depleting human CCR4+ cells in vivo: the potential application includes:
Diphtheria toxin based bivalent human IL-2 fusion toxin (SuperOntak) for depleting human CD25+ cells in vivo: in vitro efficacy characterization demonstrated that the SuperOntak is 100 times more effective than the FDA-approved monovalent human IL-2 fusion toxin, denileukin diffitox (Ontak®). The potential applications include:
Diphtheria toxin-based immunotoxin/fusion toxins for swine models:
Back to Top